Oxford Immunotec Global PLC announced it has entered into an exclusive distribution agreement with RIKEN Genesis Co., Ltd, a subsidiary of The Sysmex Corporation (Sysmex), in Japan. Under the agreement, RIKEN Genesis will exclusively distribute the T-SPOT Discovery SARS-CoV-2 kit (Research Use Only), developed by Oxford Immunotec for the detection and measurement of SARS-CoV-2 specific T cells, which may offer new insight into immunity to SARS-CoV-2 infection. Based on the company's T-SPOT technology, the only globally approved ELISPOT currently used clinically for the diagnosis of Tuberculosis infection; the T-SPOT Discovery SARS-CoV-2 kit is already available for research use across Europe and the USA. Trial data recently released by Public Health England1 using the T-SPOT Discovery SARS-CoV-2 kit suggests that individuals with SARS-CoV-2 specific T cells but without detectible antibodies (serology) may be protected from infection.